Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02414958
Registration number
NCT02414958
Ethics application status
Date submitted
8/04/2015
Date registered
13/04/2015
Date last updated
3/01/2019
Titles & IDs
Public title
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
Query!
Scientific title
A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
Query!
Secondary ID [1]
0
0
2014-001922-14
Query!
Secondary ID [2]
0
0
1245.69
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 1
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Empagliflozin
Treatment: Drugs - Empagliflozin
Treatment: Drugs - Placebo
Experimental: Empagliflozin low dose - Empagliflozin tablets once daily
Experimental: Empagliflozin high dose - Empagliflozin tablets once daily
Placebo Comparator: Placebo - Placebo tablets matching empagliflozin once daily
Treatment: Drugs: Empagliflozin
Treatment: Drugs: Empagliflozin
Treatment: Drugs: Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26
Query!
Assessment method [1]
0
0
Change from baseline in glycated haemoglobin (HbA1c) for full analysis set (FAS) (observed cases [OC]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline. Restricted maximum likelihood estimation based on mixed-effect model for repeated measures (MMRM) analysis was used to obtain adjusted means for the treatment effects.
Query!
Timepoint [1]
0
0
Baseline to week 26
Query!
Primary outcome [2]
0
0
Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) )
Query!
Assessment method [2]
0
0
Change from baseline in glycated haemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data [OC-AD]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline. Restricted maximum likelihood estimation based on mixed-effect model for repeated measures (MMRM) analysis was used to obtain adjusted means for the treatment effects.
Query!
Timepoint [2]
0
0
Baseline to week 26
Query!
Secondary outcome [1]
0
0
Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycaemia Adverse Events (AEs) With Confirmed Plasma Glucose (PG)
Query!
Assessment method [1]
0
0
This is a key secondary endpoint. Rate per patient-year of investigator-reported symptomatic hypoglycaemia adverse events (AEs) with confirmed plasma glucose (PG) <54 milligram per deciliter (mg/dL) (<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycaemia AEs (i.e. all investigator-reported AEs that had confirmed PG <54 mg/dL [<3.0 mmol/L] with symptoms reported and all severe hypoglycaemia events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate.
Query!
Timepoint [1]
0
0
Week 5 to Week 26, Week 1 to Week 26
Query!
Secondary outcome [2]
0
0
Change From Baseline in Body Weight at Week 26
Query!
Assessment method [2]
0
0
Change from baseline in body weight is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.
Query!
Timepoint [2]
0
0
Baseline to week 26
Query!
Secondary outcome [3]
0
0
Change From Baseline in Percentage of Time Spent in Target Glucose Range From Weeks 23 to 26
Query!
Assessment method [3]
0
0
Change from baseline in the percentage of time spent in target glucose range of >70 to =180 mg/dL (>3.9 to =10.0 mmol/L) as determined by continuous glucose monitoring (CGM) is presented in week 23 to 26. Least squares mean is actually an adjusted event rate.
Query!
Timepoint [3]
0
0
Week 23 to 26
Query!
Secondary outcome [4]
0
0
Change From Baseline in Interstitial Glucose Variability Based on the Interquartile Range (IQR) as Determined by CGM in Weeks 23 to 26
Query!
Assessment method [4]
0
0
Change from baseline in interstitial glucose variability based on the IQR as determined by CGM is presented for week 23 to 26. Least squares mean is actually an adjusted event rate.
Query!
Timepoint [4]
0
0
Week 23 to 26
Query!
Secondary outcome [5]
0
0
Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26
Query!
Assessment method [5]
0
0
Change from baseline in TDID is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.
Query!
Timepoint [5]
0
0
Baseline to week 26
Query!
Secondary outcome [6]
0
0
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26
Query!
Assessment method [6]
0
0
Change from baseline in SBP and DBP is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomised trial medication. Least squares mean is adjusted mean change from baseline.
Query!
Timepoint [6]
0
0
Baseline to week 26
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- Male or female patient receiving insulin for the treatment of documented diagnosis of
Type 1 Diabetes Mellitus (T1DM) for at least 1 year at the time of Visit 1
- Fasting C-peptide value of < 0.7 ng/mL (0.23 nmol/L) at Visit 2 measured by the
central laboratory
- Use of, and be willing, based on the Investigator's judgement, to continue throughout
the duration of the trial, either:
- Multiple Daily Injections (MDI) of insulin consisting of at least one basal
insulin injection and at least three daily bolus injections OR
- Continuous Subcutaneous Insulin Infusion (CSII) of any insulin type, with at
least 5 months experience of using CSII prior to Visit 1
- HbA1c >/= 7.5% and </= 10.0% at Visit 5 measured by the central laboratory
- Age >/= 18 years at Visit 1
Additional inclusion criteria may apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- History of Type 2 Diabetes Mellitus (T2DM), maturity onset diabetes of the young
(MODY), pancreatic surgery or chronic pancreatitis
- Pancreas, pancreatic islet cells or renal transplant recipient
- T1DM treatment with any other antihyperglycaemic drug (e.g. metformin,
alpha-glucosidase inhibitors, Glucagon-like-peptide 1 (GLP-1) analogues,
Sodium-Glucose Co-Transporter (SGLT-2) inhibitors, pramlintide, inhaled insulin,
pre-mixed insulins etc.) except subcutaneous basal and bolus insulin within 3 months
prior to Visit 1
- Occurrence of severe hypoglycaemia involving coma/unconsciousness and/or seizure that
required hospitalisation or hypoglycaemia-related treatment by an emergency physician
or paramedic within 3 months prior to Visit 1 and until randomisation
- Occurence of Diabetic Ketoacidosis (DKA) within 3 months prior to Visit 1 and until
randomisation
Additional exclusion criteria may apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/06/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/10/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
730
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
Coffs Endocrine & Diabetes Services - Coffs Harbour
Query!
Recruitment hospital [2]
0
0
AIM Centre - Merewether
Query!
Recruitment hospital [3]
0
0
Royal Brisbane & Women's Hospital-Endocrinology - Herston
Query!
Recruitment postcode(s) [1]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [2]
0
0
2291 - Merewether
Query!
Recruitment postcode(s) [3]
0
0
4006 - Herston
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Nebraska
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Nevada
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Hampshire
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Utah
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Washington
Query!
Country [18]
0
0
Austria
Query!
State/province [18]
0
0
Feldkirch
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Steyr
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Wien
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Arlon
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Bonheiden
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Brussel
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Bruxelles
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Edegem
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Gent
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
La Louvière
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Leuven
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Liège
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Merksem
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Alberta
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
British Columbia
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Manitoba
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Migration Data
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Nova Scotia
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Ontario
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Quebec
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Praha 2
Query!
Country [39]
0
0
Czechia
Query!
State/province [39]
0
0
Slany
Query!
Country [40]
0
0
Czechia
Query!
State/province [40]
0
0
Usti nad Labem
Query!
Country [41]
0
0
Denmark
Query!
State/province [41]
0
0
Aalborg
Query!
Country [42]
0
0
Denmark
Query!
State/province [42]
0
0
Aarhus C
Query!
Country [43]
0
0
Denmark
Query!
State/province [43]
0
0
Gentofte
Query!
Country [44]
0
0
Denmark
Query!
State/province [44]
0
0
Hillerød
Query!
Country [45]
0
0
Denmark
Query!
State/province [45]
0
0
Køge
Query!
Country [46]
0
0
Finland
Query!
State/province [46]
0
0
Kuopio
Query!
Country [47]
0
0
Finland
Query!
State/province [47]
0
0
Oulu
Query!
Country [48]
0
0
Finland
Query!
State/province [48]
0
0
Turku
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Caen
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
La Rochelle Cedex 1
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Narbonne
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Reims
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Vandoeuvre-lès-Nancy
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Vénissieux
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Aschaffenburg
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Asslar
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Berlin
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Essen
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Pirna
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Rehlingen-Siersburg
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Saarbrücken
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Saint Ingbert/Oberwürzbach
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Schweinfurt
Query!
Country [64]
0
0
Netherlands
Query!
State/province [64]
0
0
Alkmaar
Query!
Country [65]
0
0
Netherlands
Query!
State/province [65]
0
0
Amsterdam
Query!
Country [66]
0
0
Netherlands
Query!
State/province [66]
0
0
Arnhem
Query!
Country [67]
0
0
Netherlands
Query!
State/province [67]
0
0
Groningen
Query!
Country [68]
0
0
Netherlands
Query!
State/province [68]
0
0
Hoogeveen
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Rotterdam
Query!
Country [70]
0
0
Netherlands
Query!
State/province [70]
0
0
Zwijndrecht
Query!
Country [71]
0
0
Norway
Query!
State/province [71]
0
0
Hamar
Query!
Country [72]
0
0
Norway
Query!
State/province [72]
0
0
Lørenskog
Query!
Country [73]
0
0
Norway
Query!
State/province [73]
0
0
Oslo
Query!
Country [74]
0
0
Norway
Query!
State/province [74]
0
0
Ålesund
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Bialystok
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Krakow
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Lublin
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Poznan
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Radom
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Rzeszow
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Warsaw
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Barcelona
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Granada
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Malaga
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Segovia
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Sevilla
Query!
Country [87]
0
0
Sweden
Query!
State/province [87]
0
0
Borås
Query!
Country [88]
0
0
Sweden
Query!
State/province [88]
0
0
Karlstad
Query!
Country [89]
0
0
Sweden
Query!
State/province [89]
0
0
Vällingby
Query!
Country [90]
0
0
Taiwan
Query!
State/province [90]
0
0
Taichung
Query!
Country [91]
0
0
Taiwan
Query!
State/province [91]
0
0
Tainan
Query!
Country [92]
0
0
Taiwan
Query!
State/province [92]
0
0
Taipei
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Buckinghamshire
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Cambridge
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Edinburgh
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Leicester
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
London
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Nottingham
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Nuneaton
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Surrey
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Welwyn Garden City
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Eli Lilly and Company
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin
regimen of multiple daily injections (MDI) or continuous subcutaneous insulin infusion
(CSII). Randomisation to 3 treatments arms (equal assignment) following a screening period,
an optimisation period and a run-in period. 52 week double-blind treatment period, and 3 week
follow-up period.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02414958
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02414958
Download to PDF